Pipeline
Advancing drug candidates with the goal of delivering transformative medicines for patients
Our ReSOLVE™ platform enables a highly differentiated pipeline of small molecule therapeutics for highly validated innate immunity targets. Our lead programs target the inflammasome and nucleic acid sensing pathways. We have multiple programs in discovery and are pursuing a broad pipeline of additional targets.
| Program | Discovery | Lead Optimization | IND-Enabling | Phase 1 | Phase 2 |
|---|
| cGAS Franchise | |||||
| VENT-03 Immunology, Inflammation, Dermatology | |||||
| Brain-Penetrant Neuroinflammation, Neurodegeneration | |||||
| Next-Gen Systemic | |||||
| Topical | |||||
| NLRP3 Franchise | |||||
| VENT-02 Neuroinflammation, Neurodegeneration | |||||
| Next-Gen Brain-Penetrant | |||||
| Wholly Owned Systemic Inflammation, Pulmonology | |||||
| VENT-01 Nephrology, Cardiology, Hepatology |  | ||||
| Undisclosed | |||||
| Brain-Penetrant Neuroinflammation, Neurodegeneration | |||||
| Systemic Immunology, Gastroenterology | |||||
| Undisclosed | |||||
| Systemic | |||||
| Multiple programs in discovery, powered by ReSOLVE™ | ||||
| cGAS Franchise | ||
| VENT-03 | ||
| Immunology, Inflammation, Dermatology | ||
| Phase 1 | ||
| Brain-Penetrant | ||
| Neuroinflammation, Neurodegeneration | ||
| Lead Optimization | ||
| Next-Gen Systemic | ||
| Lead Optimization | ||
| Topical | ||
| Lead Optimization | ||
| NLRP3 Franchise | ||
| VENT-02 | ||
| Neuroinflammation, Neurodegeneration | ||
| Phase 1 | ||
| Next-Gen Brain-Penetrant | ||
| Lead Optimization | ||
| Wholly Owned Systemic | ||
| Inflammation, Pulmonology | ||
| Lead Optimization | ||
| VENT-01 | ||
| Nephrology, Cardiology, Hepatology | ||
| Phase 1 | ||
| Undisclosed | ||
| Brain-Penetrant | ||
| Neuroinflammation, Neurodegeneration | ||
| Lead Optimization | ||
| Systemic | ||
| Immunology, Gastroenterology | ||
| Lead Optimization | ||
| Undisclosed | ||
| Systemic | ||
| Lead Optimization | ||
Multiple programs in discovery, powered by ReSOLVE™
